ATAI vs ATOS

AtaiBeckley Inc. vs Atossa Therapeutics, Inc. — Valuation Comparison 2026

ATAI

Biotechnology
AtaiBeckley Inc.
Quality
4.9
out of 10
Value Trap
Price
$4.41
Last close
Models
5/13
Active
VS

ATOS

Biotechnology
Atossa Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$5.19
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ATAI Fair ValueATAI Upside ATOS Fair ValueATOS Upside
Bayesian DCF Intrinsic $1.04 -76.5% $3.40 -34.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.35 -46.8% $0.52 -90.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATAI vs ATOS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATAI vs ATOS — Which Stock Is More Undervalued?

ATAI scores higher with a 4.9/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AtaiBeckley Inc. (ATAI) and Atossa Therapeutics, Inc. (ATOS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATAI currently trades at $4.41 with a QOC of 4.9/10, while ATOS trades at $5.19 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).